NextCure, Inc. (NXTC)
| Market Cap | 7.49M -46.2% |
| Revenue (ttm) | n/a |
| Net Income | -54.66M |
| EPS | -15.32 |
| Shares Out | 3.61M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 215,588 |
| Open | 2.410 |
| Previous Close | 2.230 |
| Day's Range | 2.000 - 2.500 |
| 52-Week Range | 2.000 - 15.740 |
| Beta | 1.30 |
| Analysts | Strong Buy |
| Price Target | 19.33 (+831.57%) |
| Earnings Date | May 7, 2026 |
About NXTC
NextCure, Inc., a clinical-stage biopharmaceutical company, engages in advancing medicines to treat cancer. The company’s product candidate is the LNCB74, a B7-H4 targeted ADC to kill tumors. It also develops NC410, a fusion protein of LAIR-2, that is designed to block immune suppression mediated by LAIR-1; NC525, a novel LAIR-1 antibody that targets acute myeloid leukemia, blast cells, and leukemic stem cells; NC181 a humanized antibody targeting ApoE4 for the treatment of Alzheimer’s disease; and NC605 an antibody that targets Siglec-15, as w... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 3 analysts, the average rating for NXTC stock is "Strong Buy." The 12-month stock price target is $19.33, which is an increase of 831.57% from the latest price.
News
NXTC Announces Replay Available for Virtual KOL Event Discussing ASCO 2026 Dose Escalation Data from Phase 1 Trial of SIM0505 for Gynecologic Cancers
BELTSVILLE, Md., June 04, 2026 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel therapies to treat cancer, to...
NextCure Transcript: KOL event
SIM0505, a CDH6-targeting ADC, showed a 55% response rate in heavily pretreated gynecologic cancers, with favorable safety and low ILD risk. Dose optimization is ongoing, and the drug may address significant unmet needs in ovarian and uterine serous carcinoma.
NextCure Press release: KOL event
NextCure issued a press release on June 2, 2026, disclosing material business information to investors.
NextCure Slides: KOL event
NextCure has posted slides in relation to its latest quarterly earnings report, which was published on June 2, 2026.
NextCure share weakness overdone, says Lucid Capital
Lucid Capital analyst Christopher Liu says NextCure’s (NXTC) SIM0505 data “were relatively encouraging,” despite the shares trading down 45%. The weakness is overdone, and Lucid would be buyers at the...
NextCure presents Phase 1 data for SIM0505 in gynecologic cancers
NextCure (NXTC) and Simcere Zaiming Pharmaceutical announced positive Phase 1 dose escalation data for SIM0505, an antibody-drug conjugate targeting CDH6, presented at the American Society for Clinica...
NextCure Presents Positive SIM0505 Phase 1 Dose Escalation Data in Patients with Gynecologic Cancers at ASCO 2026
55% ORR in gynecologic cancers with 52.9% in ovarian and 66.7% in USC at 12 weeks by best response per RECIST 1.1 within the therapeutic dose range (4.8 – 8.0 mg/kg) Favorable safety and tolerability ...
NextCure initiated with a Buy at Lucid Capital
Lucid Capital initiated coverage of NextCure (NXTC) with a Buy rating and $25 price target NextCure is a clinical stage biotechnology company focused on developing antibodydrug conjugates for cancer p...
NextCure reports Q1 EPS ($1.87), consensus ($2.03)
“Our SIM0505 program reached critical milestones this quarter, headlined by the U.S. Food and Drug Administration (FDA) granting Fast Track designation for platinum-resistant ovarian cancer and the up...
NextCure Provides Business Update and Reports First Quarter 2026 Financial Results
BELTSVILLE, Md., May 07, 2026 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel therapies to treat cancer, tod...
NextCure Quarterly report: Q1 2026
NextCure has published its Q1 2026 quarterly earnings report on May 7, 2026.
NextCure Earnings release: Q1 2026
NextCure released its Q1 2026 earnings on May 7, 2026, summarizing the period's financial results.
NextCure Slides: Corporate presentation
NextCure has posted slides in relation to its latest quarterly earnings report, which was published on May 7, 2026.
NextCure initiates dose optimization portion of SIM0505 study
NextCure (NXTC) announced initiation of the dose optimization portion of the Phase 1 study of SIM0505, focusing on patients with platinum-resistant ovarian cancer. SIM0505 is an investigational antibo...
NextCure and Simcere Zaiming Initiate Dose Optimization for SIM0505 (CDH6 ADC) in Gynecologic Cancers
BELTSVILLE, Md., May 04, 2026 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class, and best-in-c...
NextCure Proxy statement: Proxy filing
NextCure filed a proxy statement on April 24, 2026, providing details for shareholder voting and corporate governance matters.
NextCure Proxy statement: Proxy filing
NextCure filed a proxy statement on April 24, 2026, providing details for shareholder voting and corporate governance matters.
NextCure and Simcere's SIM0505 (CDH6 ADC) Phase 1 Data to be Presented at ASCO 2026
Poster to be presented at the American Society for Clinical Oncology on Monday, June 1, 2026 Poster to be presented at the American Society for Clinical Oncology on Monday, June 1, 2026
NextCure granted Fast Track Designation for SIM0505 by FDA
NextCure (NXTC) announced that the FDA has granted Fast Track Designation for SIM0505 for the treatment of platinum-resistant ovarian cancer. SIM0505 is an investigational antibody drug conjugate comp...
NextCure Receives Fast Track Designation for SIM0505 (CDH6 ADC) in Ovarian Cancer
BELTSVILLE, Md., April 07, 2026 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class, and best-in...
NextCure and Simcere's SIM0505 (CDH6 ADC) Abstract Accepted for ASCO 2026
BELTSVILLE, Md., March 31, 2026 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class, and best-in...
NextCure Provides Business Update and Reports Full Year 2025 Financial Results
BELTSVILLE, Md., March 05, 2026 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class, and best-in...
NextCure Annual report: Q4 2025
NextCure has published its Q4 2025 annual report on March 5, 2026.
NextCure Earnings release: Q4 2025
NextCure released its Q4 2025 earnings on March 5, 2026, summarizing the period's financial results.